Myriad Genetics Reports Solid Q3 2024 Growth Amid Challenges
Myriad Genetics ( (MYGN) ) has released its Q3 earnings. Here is a breakdown of the information Myriad Genetics presented to its investors.
Business Wire2d
MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the Firm
NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. (“Myriad” or “the Company”) ...
Zacks.com on MSN2d
Compared to Estimates, Myriad (MYGN) Q3 Earnings: A Look at Key Metrics
Myriad Genetics (MYGN) reported $213.3 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 11.2%. EPS of $0.06 for the same period compares to -$0.03 a ...
Zacks.com on MSN2d
Myriad Genetics (MYGN) Q3 Earnings and Revenues Surpass Estimates
Myriad Genetics (MYGN) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.03 per share a year ago. These figures ...
Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance
HighlightsThird quarter revenue grew 11% year-over-year to $213 million, driven by Pharmacogenomics (34%) and Prenatal (10%) and progress on ...
StamfordAdvocate3d
Myriad: Q3 Earnings Snapshot
SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Myriad Genetics Inc. (MYGN) on Thursday reported a loss of $22.1 million in its third quarter. On a per-share basis, the Salt Lake City-based company said ...
Today5d
Jill Martin raises awareness of genetic testing for breast cancer on Football Night in America
Ahead of the Bengals-Giants game on Sunday, Oct. 13, Jill joined the program to discuss her history with breast cancer and urge viewers to consider genetic testing if they're high risk — a step ...